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Background: Multiple myeloma (MM) is a hematologic malignancy that is characterized by the proliferation of
abnormal bone marrow plasma cells (BMPC) and overproduction of immunoglobulin or light chains with evidence
of end-organ damage such as bone damage, anemia, hypercalcemia, and renal dysfunction. The pathogenesis of MM
is closely linked to dysregulated unfolded protein response (UPR) in the endoplasmic reticulum (ER). Constitutive
activation of UPR in mice, as demonstrated by transgenic expression of a master UPR transcription factor XBP1s
(a UPR-specific splice variant of X-box binding protein 1), causes myeloma. grp94 (gp96) is a key downstream
chaperone in the ER that mediates the UPR as a part of the protein quality control mechanism in the secretory
pathway. Our recent study has shown that the persistence of plasma cells as well as the development of myeloma in
XBP1s-transgenic mice is critically dependent on grp94. However, the role of grp94 in the initiation and progression of
human MM is still unknown.
Methods: The expression level of grp94 in BMPCs was measured by flow cytometry, real-time RT-PCR, and
Western blot analysis. We compared the expression levels of grp94 in BMPCs in a spectrum of patients including
MM, monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), as well as non-plasma
cell disorders (NPC).
Results: We found that grp94 was highly expressed in malignant plasma cells in patients with MM, but not in BMPCs
in patients with MGUS/SMM and NPC. The expression level of grp94 correlated significantly with CD138 expression
level. We also found that the grp94 expression level in BMPCs from International Staging System (ISS) stage III MM
patients is higher than those in ISS stage I/II MM patients.
Conclusions: grp94 is highly expressed in BMPCs in MM, which correlates with the advanced stage of this disease. Our
data demonstrated that grp94 is a novel diagnostic and prognostic biomarker. It also positioned grp94 as a promising
therapeutic target for MM.
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Despite the introduction of new treatments, multiple
myeloma (MM) remains an incurable malignant plasma
cell disorder [1–11]. It is the second most common
hematologic malignancy, and it accounts for 10 % of all
hematological malignancies [12–15]. Each year, over
20,000 new cases are diagnosed in the United States of
America [16]. MM is a cytogenetically heterogeneous
clonal disorder [13, 17, 18]. It typically evolves from an
asymptomatic pre-malignant stage called monoclonal
gammopathy of undetermined significance (MGUS)
[19–21], to an intermediate asymptomatic smoldering
MM (SMM) [22], to eventually symptomatic MM. SMM
is a biologically heterogeneous entity [23] which includes
patients similar to those with MGUS with a very low
rate of progression, as well as those who develop clinic-
ally evident end-organ damage within the first 2 years of
diagnosis [24, 25]. No single pathological or molecular
feature can be used to distinguish MM patients from
SMM, who have clonal pre-malignant plasma cells from
those with clonal myeloma cells.
Durie and Salmon introduced a staging system in 1975
that used M protein, hemoglobin, calcium, and the num-
ber of bone lesions to predict MM cell tumor burden
[26]. In the 1980s, serum β2-microglobulin (β2M) was
found to be a simple but reliable prognostic marker for
staging of MM [27, 28]. Subsequently, albumin [29] and
bone marrow plasma cell (BMPC) proliferation indices
[30, 31] were found to be useful prognostic factors. The
International Staging System (ISS) was devised in 2005
using β2M and serum albumin level, which enabled sta-
ging the patients clinically and ascertaining their prog-
noses [32]. This has been further refined by combining
FISH data with ISS [33, 34]. Other types of biomarkers
(including serum free light chain (sFLC) ratio and cyto-
genetic markers) also provide prognostic information on
myeloma and for patients with asymptomatic plasma cell
disorders [34–37]. Recent studies showed that CD44
expression is significantly higher in plasma cells from
persistent/relapsed MM than untreated patients [38]. N-
cadherin protein and gene expression are increased in
CD38highCD138+ plasma cells from MM patients, and
high expression of N-cadherin correlates with shorter
progression-free survival and overall survival comparing
with patients with normal N-cadherin level [39]. More
recently, it was found that serum miRNA-483-5P is sig-
nificantly elevated in MM patients, and high expression of
miRNA-483-5P is associated with shorter progression-free
survival [40]. Insulin-like growth factor binding protein 7
(IGFBP7) expression is associated with the poor prognosis
with the absence of myeloma bone disease [41].
The clinical outcome of MM has significantly im-
proved in the last decade due to introduction of the new
class of therapeutic agents [42, 43]. Until the 1990s, fewadvances in treatment of the MM occurred and the me-
dian survival of newly diagnosed myeloma patients was
2.5 years [42]. However, beginning in the mid-1990s,
with the introduction of high-dose melphalan and au-
tologous hematopoietic cell transplantation (AHCT),
survival began to improve [44]. From late 1990s to mid-
2000s, the overall median survival increased to nearly
4 years [42]. Further improvement in disease control
and survival were made in the mid-2000s with the intro-
duction of highly active agents with mechanisms of action
independent of DNA damage [42]. Immunomodulatory
drugs (IMiDs) such as thalidomide and lenalidomide and
proteasome inhibitors (PI) such as bortezomib are the few
examples of these novel agents [45]. However, nearly all
MM patients eventually relapse. High rates of relapse sug-
gest that clinically undetectable minimal residual disease
persists after treatment, and proliferation of the remaining
myeloma cells ultimately results in relapse [18, 46]. There-
fore, sensitive and specific early diagnostic and prognostic
biomarkers remain necessary for MM.
Molecular chaperone grp94 [47], also known as gp96
[48], endoplasmin [49], ERp99 [50], and HSP90b1 [51],
is an endoplasmic reticulum (ER) paralog of HSP90.
grp94 is a key downstream chaperone to mediate un-
folded protein response (UPR) [52]. UPR is an evolution-
ally conserved mechanism that maintains protein quality
control in the secretory pathway. Accumulation of mis-
folded proteins in the ER triggers the activation of three
well-known pathways: activating transcription factor 6
(ATF6), the double-stranded RNA-activated protein
kinase-like ER kinase (PERK), and the spliced form of X-
box binding protein 1 (XBP1s). These induce the expres-
sion of the major ER heat shock proteins including
grp94, grp78, and calreticulin, which together enhance
the protein folding machinery [53, 54]. The pathogenesis
of MM is closely linked to dysregulated UPR in the ER
[55]. Constitutive activation of UPR in mice, as demon-
strated by transgenic expression of a master UPR tran-
scription factor XBP1s, causes myeloma [56]. Our recent
study has shown that the persistence of plasma cells as
well as the development of myeloma in XBP1s-transgenic
mice is critically dependent on grp94 [57]. However, the
role of grp94 in the initiation and progression of human
MM is still unknown. In this study, we examined the ex-
pression levels of grp94 in BMPCs from patients with
plasma cell disorders and non-plasma cell diseases. We
found that high expression of grp94 in BMPCs is a novel
molecular hallmark of MM.
Results
Patient characteristics
Patient characteristics in this study are summarized in
Table 1. The median age was 57 years (range 32–75) for
MM patients, 62 years (range 54–72) for MGUS/SMM
Table 1 Clinical characteristics of patients
MM MGUS and SMM NPC
(n) (n) (n)
Total 20 7 15
Male 12 2 12
Female 8 5 3





Type of monoclonal component
IgG, κ 10 3
IgG, λ 1 2
IgA 2 1
Light chain 7 1
Non-secretory 0
β2 microglobulin 5.8
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The male-to-female ratios were 1.5:1 in MM, 1:2.5 in
MGUS/SMM, and 4:1 in NPC. Based on the ISS staging
system [32], 4 MM patients were in stage I, 1 patient in
stage II, and 13 patients in stage III at the time of diag-
nosis. The monoclonal component was of IgGκ type in
ten patients, IgGλ type in one patient, IgA type in two
patients, and light chain disease in seven patients. The
median number of prior treatment regimens for MM
was two. Three MM patients were treated with autolo-
gous hematopoietic cell transplantation. Fifteen NPC pa-
tients include 5 diffuse large B cell lymphoma (DLBCL)
patients with active disease, 2 acute myelogenous
leukemia (AML) patients with active disease, 3 AML pa-
tients with no disease, 1 mantle cell lymphoma (MCL)
patient with active disease, 1 marginal zone B cell
lymphoma (MZL) patient with stage IV active disease, 1
Hodgkin lymphoma (HL) patient with active disease, 1
aplastic anemia (AA) patient, and 1 carcinoma patient
with gastrointestinal (GI) primary.
grp94 is preferentially expressed in plasma cells
We first examined the protein expression level of grp94
on various cellular populations in the bone marrow (BM)
using flow cytometry after intracellular staining with a
highly specific monoclonal antibody against grp94.Remarkably, although grp94 is thought to be constitutively
expressed by all nucleated cells [52], we found that the ex-
pression level of grp94 in human BM cells in MM is ex-
tremely heterogeneous. Non-B cells (population I: CD38
−CD138− cells), which are mostly myeloid cells, express
grp94 at very low level. By comparison, plasma cells
(population IV: CD38highCD138+ cells) express the highest
level of grp94, followed by pro- and pre-B cells (popula-
tion III: CD38intCD138− cells) and naïve B cells (popula-
tion II: CD38lowCD138− cells) (Fig. 1a, b).
We next corroborated our findings by determining the
mRNA expression level of grp94 in BMPCs in MM pa-
tients by real-time RT-PCR as well as Western blot. We
isolated CD138+ PCs and CD138− non-plasma cells from
BM cells from MM patients using magnetic beads,
followed by purification of total mRNA and real-time
RT-PCR using primers specific for human grp94 cDNA.
18S ribosomal RNA was used as an internal control. We
found that grp94 transcript level in CD138+ BMPCs was
more than 15-fold higher than CD138− cells (Fig. 2a).
Consistently, the significant high expression level of
grp94 in CD138+ PCs was also confirmed by Western
blot (Fig. 2b).grp94 is highly expressed in malignant plasma cells in
MM
We next determined if the high level of grp94 expression
is unique to BMPCs of MM patients by broadening our
analysis to patients with MGUS/SMM as well as NPC.
As expected, BMPCs from MM patients expressed a sig-
nificantly higher level of grp94, compared with BMPCs
from patients with MGUS/SMM and NPC (Fig. 3a).
CD138 (syndecan-1) is a specific marker of human
plasma cells [58]. We found indeed that the expression
of grp94 paralleled with CD138 level (Fig. 3c, left panel)
in MM patients. However, while grp94 expression level
separated out MGUS/SMM from NPCs, CD138 level
failed to do so (Fig. 3a, b), demonstrating that grp94 ex-
pression is a better diagnostic marker than CD138 for
malignant plasma cell disorder.Higher expression of grp94 is associated with worse
disease in MM
We next examined if the grp94 expression in malignant
plasma cells in MM patients has any prognostic signifi-
cance, by comparing grp94 expression level in BMPCs
with the ISS staging status [32]. We found that the ex-
pression level of grp94 correlated with the clinical out-
comes of MM patients. grp94 expression is significantly
elevated in plasma cells from stage III MM patients
compared to the ones at the stage I/II (Fig. 4). Collect-
ively, we have demonstrated that high level of grp94 ex-
pression is not only a molecular hallmark unique to
Fig. 1 grp94 is preferentially expressed on plasma cells. a Human bone marrow cells were analyzed and representative FACS plots of different
populations in MM. Histograms show the intracellular staining of grp94 on different populations (open histogram indicates grp94; shaded histogram,
isotype control). Population I CD38−CD138− cells (non-B cells), population II CD38lowCD138− cells (naïve B cells), population III CD38intCD138− cells
(pro- and pre-B cells), population IV CD38highCD138+ cells (plasma cells). b Quantification of grp94 expression in different populations of bone marrow
from the patients with MM. Error bars indicate standard error of the mean. ***p < 0.001
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ical outcomes in MM patients.
Discussion
MM is characterized by the infiltration of bone marrow
with clonal plasma cells that secrete a monoclonal pro-
tein in the majority of patients [59]. The hallmark of the
pathology is the overproduction of a secreted protein byFig. 2 grp94 is highly expressed in plasma cells. a Q-RT-PCR analysis of grp94
ribosomal RNA was used as an internal control. The quantity of transcripts for
calculated based on the number of cycles to reach the threshold of detection
grp94 of CD138+ plasma cells and CD138− non-plasma cells. β-actin was blota malignant plasma cell population, and UPR plays crit-
ical roles in the pathogenesis of MM. grp94 is a key
downstream chaperone in the ER and mediates UPR,
but its roles in human MM was unexplored [52, 60]. In
this study, we discovered for the first time that human
plasma cells express significantly high level of grp94,
when compared with other cellular populations, indicat-
ing that the plasma cells are under active ER stress.mRNA in CD138+ plasma cells and CD138− non-plasma cells. 18S
respective genes was expressed as a relative fluorescence unit (RFU),
(Ct) using the formula of 2ΔCt (Ct interest− Ct 18S rRNA). b Western blot for
ted to indicate equal loading of cell lysates
Fig. 3 grp94 is highly expressed on malignant plasma cells in MM. a Quantification of grp94 expression in the plasma cells from the patients
with MM, MGUS/SMM, and NPC. Error bars indicate standard error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001. b Quantification of CD138
expression in the plasma cells from the patients with MM, MGUS/SMM, and NPC. Error bars indicate standard error of the mean. **p < 0.01, ***p <
0.001. c Correlations between grp94 expression and CD138 expression in plasma cells from patients with MM (left panel) and patients with
MGUS/SMM (right panel)
Fig. 4 Higher expression of grp94 is associated with worse disease
in MM. Compare grp94 expression level in malignant plasma cells
from MM patients with different ISS stages. The grp94 expression
level is significantly higher in malignant plasma cells from stage III
MM patients than that from stage I/II MM patients. (p = 0.002)
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expressed in malignant plasma cells in MM, when com-
pared with MGUS/SMM and NPC. Our observation is
consistent with the notion that grp94 is critical for ma-
lignant plasma cell survival and persistence [57], but not
for benign plasma cells [61]. CD138 is commonly
expressed by plasma cells, but it is not a unique diagnos-
tic marker for MM [58]. A recent study showed that the
serum level of CD138 was significantly higher in active
MM than that in MGUS [62]. Consistent to this study,
we found that CD138 is highly expressed on plasma cells
from the MM patients, when compared with patients
with MGUS/SMM and NPC. We also observed that
grp94 expression significantly correlated with the CD138
expression in plasma cells from patients with MM, but
not with MGUS/SMM. Further studies with a larger co-
hort of patients shall solidify this conclusion. Interest-
ingly, despite a small sample size, we discovered that the
grp94 expression in malignant plasma cells likely has
prognostic significance. Its level is significantly elevated
in plasma cells from the ISS stage III MM patients in
comparison with the stage I/II. A future perspective
study is warranted to further establish both the
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grp94 expression in MM and other plasma cell
disorders.
Among many client proteins chaperoned by grp94 [52,
61, 63, 64], Wnt co-receptor low-density lipoprotein
receptor-related protein 6 (LRP6) for canonical Wnt sig-
naling depends exclusively on grp94 for folding [57, 65].
Our study thus may add significantly to the emerging
roles of Wnt signaling in MM [66–68]. Human MM
cells appear to have evidence of active Wnt signaling by
overexpressing β-catenin which promotes proliferation
of malignant cells [69]. Blocking β-catenin with small-
molecule inhibitors, AV-65 [68] or PKF115-584 [66, 67],
specifically inhibits MM cell proliferation. Our previous
study showed that in the absence of grp94, MM cells
undergo mitotic catastrophe and apoptosis which corre-
lated with decreased expression of survivin, a down-
stream target molecule of Wnt signaling [57].
Finally, grp94 might promote the pathogenesis of MM
through folding other client proteins such as integrins,
IGF, and Toll-like receptors [61, 63, 64]. Intriguingly,
grp94-selective inhibitors are already in early develop-
ment [70, 71]. Our study may therefore pave a way for
developing grp94-targeted strategy for the treatment of
MM.
Conclusions
In summary, we found that grp94 is highly expressed in
malignant plasma cells in multiple myeloma. The higher
level of grp94 is significantly associated with worse clin-
ical stage in this disease. Our data demonstrated that
grp94 is not only a specific diagnostic and prognostic




Forty-two patients at the Hollings Cancer Center, Med-
ical University of South Carolina, were enrolled in this
study. Bone marrow samples were taken from 20 pa-
tients with MM, 7 patients diagnosed with MGUS or
SMM, and 15 patients with NPC, which include DLBCL,
AML, MCL, MZL, HL, AA, and GI primary carcinoma.
This study was conducted in accordance with the ethical
guidelines and was approved by the Institutional Review
Board of the Medical University of South Carolina. In-
formed consent was obtained from all patients.
Reagents
Antibodies used for flow cytometry were obtained from
BD Biosciences (Mountain View, CA) and eBioscience
(San Diego, CA). Antibodies against grp94 Ab (9G10)
was bought from Enzo Life Sciences, Inc. (Farmingdale,
NY), and β-actin Ab (AC-74) was purchased fromSigma-Aldrich (St Louis, MO). All other chemicals were
obtained from Sigma-Aldrich (St Louis, MO) and Fisher
Scientific (Pittsburgh, PA).
Isolation of bone marrow cells
Add Histopaque-1077 to a 15-mL conical centrifuge
tube and warm to room temperature. Carefully add antic-
oagulated bone marrow aspirate onto the Histopaque-
1077 at 1:1 ratio (Sigma-Aldrich, St Louis, MO). Centri-
fuge at 400 g for 30 min at room temperature. After
centrifugation, aspirate the upper layer with a Pasteur pip-
ette to within 0.5 cm of the opaque interface containing
bone marrow cells. Discard upper layer and transfer the
opaque interface into a clean conical centrifuge tube.
Wash the cells by adding 10 mL PBS and centrifuge at
1500 rpm for 5 min.
Flow cytometry
Surface staining of cells and flow cytometry were done
as described [64, 72, 73]. To stain grp94 intracellularly,
cells were fixed in 4 % paraformaldehyde and permea-
blized in ice-cold methanol. Cells were acquired on
FACSVerse (Becton Dickinson, Franklin Lakes, NJ), and
results were analyzed with FloJo software (Tree Star,
Ashland, OR).
Quantitative RT-PCR
CD138+ and CD138− cells were isolated from BM by using
human CD138 positive selection kit (StemCell Technolo-
gies Inc., Vancouver, Canada). Total RNA was extracted
with the RNeasy Mini kit according to the manufacturer’s
protocol (Qiagen, Valencia, CA). First-strand cDNA was
synthesized with Superscript II (Invitrogen, Carlsbad, CA).
cDNA was quantified by Q-PCR with Bio-Rad CFX Con-
nect Real-Time System. Q-PCR data were analyzed with
the corresponding software, and the number of PCR cy-
cles to reach the threshold of detection (CT) was calcu-
lated. Samples were run in duplicates. 18S ribosomal RNA
(18S rRNA) was used as an internal control. The primer
sequences are as follows. Human grp94F, GCTTCG
GTCAGGGTATCTTT; human grp94R, AGGCTCTTC
TTCCACCTTTG; 18S rRNA F, CGGCTACCACATC
CAAGGAA; 18S rRNA R, GCTGGAATTACCGCGGCT.
Protein extraction and Western blot
Protein extraction and immunoblot were performed as de-
scribed previously [74]. Briefly, cells were washed three
times with ice-cold PBS and lysed in radioimmunoprecipi-
tation assay (RIPA) lysis buffer (0.01 M sodium phosphate,
pH 7.2, 150 mM NaCl, 2 mM EDTA, 1 % NP-40, 1 % so-
dium deoxycholate, 0.1 % SDS, 2 mM AEBSF, 130 mM
bestatin, 14 mM E-64, 0.3 mM aprotinin, and 1 mM leu-
peptin). Total cell lysates was resolved on denaturing and
reducing 10 % SDS-PAGE, and the proteins were
Chhabra et al. Journal of Hematology & Oncology  (2015) 8:77 Page 7 of 9transferred from the gel onto Immobilon-P membranes.
The membrane was blocked with 5 % nonfat milk in PBS
and then incubated with different Abs, followed by incu-
bation with HRP-conjugated secondary Ab. Protein bands
were visualized by using enhanced chemiluminescent sub-
strate (Pierce, Rockford, IL).
Statistical analysis
Error bars represent the standard error of the mean
(SEM). Independent-samples t tests or ANOVA were used
to compare variables between different groups. Correla-
tions between variables were assessed using Pearson cor-
relation analysis. All statistical analyses were performed
using Prism 5 software. Values of P less than 0.05 were
considered to represent statistically significant differences.
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